Search clinical trials for: QLT091001

Total 5 results

QLT Inc.

Completed

Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)

Retinitis Pigmentosa (RP)

Canada, Ireland
QLT Inc.

Completed

Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers

Healthy Human Volunteers

Canada
QLT Inc.

Completed

Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation

Impaired Dark Adaptation

United States
QLT Inc.

Completed

Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations

LCA (Leber Congenital Amaurosis) | RP (Retinitis Pigmentosa)

United States, Canada, Germany, Netherlands, United Kingdom
QLT Inc.

Completed

Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)

LCA (Leber Congenital Amaurosis) | RP (Retinitis Pigmentosa)

Canada, United States, Germany, Netherlands, United Kingdom

3

Subscribe